LPTX stock falls on all-stock deal to acquire Flame Biosciences (NASDAQ:LPTX)

word m and a made with wood building blocks, stock image

Maksim Labkouski

Oncology-focused biotech Leap Therapeutics (NASDAQ:LPTX) misplaced ~2% pre-market Tuesday after saying an settlement with privately-held Flame Biosciences to acquire the latter in an all-stock transaction.

The deal will add Flame’s ~$50M of year-end internet money, its Phase 2 most cancers candidateLPTX

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!